Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

Inaugural 'Innovation Catalyst' event empowers innovators at UConn Health to transform their exciting research ideas into ...

Top experts from Amgen, CBIZ & Intrepid discuss 2025 trends in healthcare, biotech, and life sciences. Explore key insights ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Morgan Stanley finds itself under the scrutinizing eye of FINRA over its client vetting procedures. The watchdog is probing ...

Key Points The largest healthcare stocks by market capitalization are undergoing significant sell-offs.This low-cost ETF ...

The health landscape sees pivots as companies adjust strategies: Bristol Myers and Pfizer offer discounts on Eliquis, Newcastle University's IVF technique prevents genetic diseases, and Juul's ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

The United States has rejected amendments adopted in 2024 by members of the World Health Organization to its legally binding ...

U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape vaccine, food and medicine policies.

While FDA Commissioner Marty Makary emphasizes learning and humility, the FDA has systematically removed the very experience ...